Singleton Hospital

Posted 1 year ago by Wales Gene Park

A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma. Following a stem cell transplant for myeloma, there can be no signs of the disease. This is called remission  After some time, your myeloma might come back. This is a relapse. If this happens, you can have treatment with: a targeted cancer drug (biological therapy) called thalidomide a steroid drug called dexamethasone In this trial doctors are looking at a new drug called ixazomib. Ixazomib is a targeted cancer drug called a cancer growth blocker. It blocks certain proteins that tell cancer cells to divide and grow. Everybody taking part has thalidomide, dexamethasone and ixazomib. This is re-induction treatment. Then, you might have 1 of the following: a transplant using your own stem cells...

 Multiple myeloma /  Singleton Hospital


No post found